Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04610047 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Norketotifen in Uncomplicated Influenza-like Illness
A Phase 2 study of Influenza and Influenza-like Illness, sponsored by Emergo Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 315
- Enrollment target
- 20
- Study locations
NCT04610047: Completed Phase 2 study of Influenza and Influenza-like Illness, sponsored by Emergo Therapeutics.
NCT04610047 is a Phase 2 study of Influenza and Influenza-like Illness that has completed, run by Emergo Therapeutics. The registered enrollment target is 315 participants, below the 36,802-participant average among 156 other Influenza trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04610047, a Phase 2 study of Influenza and Influenza-like Illness, has completed, sponsored by Emergo Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 315 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2b, multi-center, double-blind, randomized, placebo-controlled, parallel-group study of NKT versus placebo in otherwise healthy adults presenting with acute uncomplicated ILI due to influenza or other respiratory viruses in a community setting.
Primary Outcome
Time to alleviation of the symptoms of ILI (headache, feverishness/chills, muscle/joint pain, fatigue, cough, sore throat, nasal congestion)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Norketotifen
Study Locations (20)
Florida
- Omega Research Debary - DeBary
- The Chappel Group Research - Kissimmee
- South Florida Research Center - Miami
- Premier Research Associate - Miami
- Research Institute of South Florida - Miami
Pennsylvania
- Frontier Clinical Research - Scottdale
- Frontier Clinical Research - Smithfield
Texas
- Cedar Health Research - Dallas
- Advanced Medical Group - Houston
Arizona
- Precision Trials AZ - Phoenix
California
- Downtown LA Research Center - Los Angeles
Louisiana
- Horizon Research Group of Opelousas - Eunice
Maryland
- Continental Clinical Solutions - Towson
Nevada
- Clinical Research of South Nevada - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 315 participants |
| Start Date | 2020-12-14 |
| Est. Completion | 2022-02-09 |
| Phase | Phase 2 |
What the finished NCT04610047 record still lists
NCT04610047 is an interventional study that assigns participants to a tested intervention. The registered 315 participants enrollment target is mid-sized for trials with a published cap, below the 36,802-participant average among 156 other Influenza trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Influenza appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04610047 names 20 study sites across 14 states, led by Florida, Pennsylvania, Texas.
Frequently Asked Questions
What is clinical trial NCT04610047 about?
NCT04610047 is a clinical study titled "Efficacy and Safety of Norketotifen in Uncomplicated Influenza-like Illness". This is a Phase 2b, multi-center, double-blind, randomized, placebo-controlled, parallel-group study of NKT versus placebo in otherwise healthy adults presenting with acute uncomplicated ILI due to influenza or other respiratory viruses in a community setting.
What is the current status of trial NCT04610047?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 315 participants. The study started on 2020-12-14. Estimated completion is 2022-02-09.
What conditions does trial NCT04610047 study?
This clinical trial studies the following conditions: Influenza, Influenza-like Illness.
What interventions are being tested in trial NCT04610047?
The interventions under investigation include: Placebo (DRUG), Norketotifen (DRUG).
Who is sponsoring clinical trial NCT04610047?
This trial is sponsored by Emergo Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04610047 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04610047's enrollment target sits among peer trials
315 63rd of 156 higher than 94 of 156 other Influenza trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Influenza trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater)
RECRUITING · Phase 2
-
Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients
RECRUITING · Phase 2
-
High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients
RECRUITING · Phase 2
-
Systems Investigation of Vaccine Responses in Aging and Frailty
RECRUITING · Phase 2
-
High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
RECRUITING · Phase 2
-
High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04812366 · 315 participants · Phase 2
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
- NCT05101460 · 315 participants
An All Comers Registry For Normothermic Ex Vivo Lung Perfusion (EVLP) as Assessment of Donor Lungs for Transplant
- NCT05897320 · 315 participants · Phase 3
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
- NCT06439082 · 315 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI